A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice.
Adverse events
Allergic reactions
Biologics
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
18
05
2022
revised:
12
09
2022
accepted:
13
09
2022
pubmed:
27
9
2022
medline:
15
12
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
Biologic agents have become an integral therapeutic option for practicing allergists-immunologists for the management of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and various immunologic conditions. As these agents vary considerably from traditional small-molecule drugs, various adverse reactions have been noted. A different approach must be used to classify these reactions beyond the classic Gell-Coombs classification system as it does not capture many of the adverse events seen with biologic therapy. This article addresses the available literature on proposed classification systems and diagnostic modalities for adverse events associated with biologics and reviews each approved agent used frequently in allergy-immunology practice.
Identifiants
pubmed: 36162800
pii: S2213-2198(22)00956-4
doi: 10.1016/j.jaip.2022.09.020
pii:
doi:
Substances chimiques
Biological Products
0
Biological Factors
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3075-3086Informations de copyright
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.